Organic compounds

A medicament comprising, separately or together

• (A) a glycopyrronium salt;
• (R)-3-(2-Hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide or ((R)-3-((R)-2-cyclohexyl-2-hydroxy-2-phenylacetoxy)-1-(isoxazol-3-ylcarbamoylmethyl)-1-azoniabicyclo[2.2.2]octane;
• (B) a beta-2 adrenoceptor agonist selected from salmeterol and formoterol, or pharmaceutically acceptable salts thereof;
• and
• (C) corticosteroid selected from fluticasone propionate, 4-Methyl-thiazole-5-carboxylic acid (6S,9R,10S,11S,13S,16R,17R)-6,9-difluoro-17 fluoromethylsulfanylcarbonyl-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl ester, Furan-2-carboxylic acid (6S,9R,10S,11S,13S,16R,17R)-6,9-difluoro-17-fluoromethylsulfanylcarbonyl-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl ester, and budesonide;
• and 3-methyl-thiophene-2-carboxylic acid (6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta-a]phenanthren-17-yl ester;
• for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.